Genetic testing can tell you what your patients can’t.

The GeneSight® test provides information about your patient that may help you avoid multiple medication trials.

The GeneSight Psychotropic test is a pharmacogenomic test that analyzes clinically important genetic variations which may impact how your patient metabolizes and responds to certain medications used to treat mental health conditions. The test is a powerful tool to augment your knowledge, experience and passion for your patients.

In a post-hoc analysis of data from the GUIDED study, the GeneSight Psychotropic test was found to significantly improve clinical outcomes in patients taking medications with gene-drug interactions compared to treatment as usual.1

  • Remission
  • Response
  • Symptom improvement

2 million patients and counting

Tens of thousands of clinicians have ordered the GeneSight test for 2 million patients and counting.

7 clinical studies

7 clinical studies published in peer-reviewed journals support the GeneSight test’s effectiveness. GeneSight Psychotropic is the only psychiatric pharmacogenomic test backed by such extensive research.

A comprehensive report, personalized for your patient.

The GeneSight® Psychotropic report provides information about which medications may require dose adjustments, be less likely to work, or have an increased risk of side effects based on your patient’s genetic information.

The report categorizes medications into three color-coded categories and applies clinical considerations to explain the rationale for a medication’s classification. This information can be used to help inform treatment decisions.

Genotype/phenotype information is provided for 5 pharmacodynamic and 9 pharmacokinetic genes. COMT is also included for informational purposes.

The gene-drug interaction chart provides information on which pharmacokinetic genes are involved in the metabolism of each medication.

  •  Use as directed
  •  Moderate gene-drug interaction
  •  Significant gene-drug interaction

Cost shouldn’t be a barrier to the GeneSight® test.

We will bill your patient’s insurance for the cost of the GeneSight test:

  • Medicare (Part B) Covered Tests – $0 out of pocket cost for your patient
  • Medicare Advantage Covered Tests – your patient may be expected to cover a portion of the cost (typically $330 or less) and the GeneSight Promise applies
  • Medicaid – typically, your patient will have a $0 out of pocket cost
  • Commercial or Other Insurance – plans vary, but your patient may be expected to cover a portion of the cost (typically $330 or less) and the GeneSight Promise applies
  • Uninsured – if the GeneSight test is not covered by your insurance, or if your portion of the cost is estimated to be higher than $330, you may want to consider the reduced Self-Pay option.

If your patient doesn’t have insurance, please contact our Customer Service team to find out how we can help.

We also offer a payment plan and a financial assistance program to help patients with their out of pocket cost. Learn more about these programs at GeneSight.com/cost

98%of patients pay $330 or less for their GeneSight test*
$0is the typical out-of-pocket cost for patients on Medicare (Part B) and Medicaid

We also offer a payment plan and a financial assistance program to help patients with their out of pocket cost. Learn more about these programs at GeneSight.com/cost

The GeneSight Promise

If you decide to use your insurance and we determine that your cost will exceed $330, we will contact you before processing the test and before billing you to make sure you would like to proceed.

Reduced self-pay option

All patients are eligible for the reduced Self-Pay option of $330. Self-Pay may be the most affordable option for patients whose out-of-pocket cost is estimated to be higher than $330, for those whose insurance does not cover the GeneSight test, or for those without insurance.

Who can benefit from the GeneSight test?

Fewer than 50% of patients with depression respond to their first prescribed medication and with each failed medication trial, their treatment intolerance increases.2

Consider offering the GeneSight test to:

  • New patients with a previous medication failure
  • Patients who are experiencing lower than desired medication response
  • Patients who are currently experiencing unwanted side effects
  • Elderly patients and patients with liver damage
RX Icon

The GeneSight test delivers genetic insights that may inform your treatment plan and potentially shorten your patients’ road to recovery.

The GeneSight Psychotropic test can provide information
that your patients can’t.

To order the GeneSight test or request additional information, contact your sales representative or email [email protected]

Customer service
[email protected]
866.757.9204

Medical information
[email protected]
855.891.9415

Not all patients who receive the GeneSight test will have improved outcomes. The GeneSight test is intended to supplement a clinician’s comprehensive medical assessment.

*Based on a review of six months of past claim data for major insurance carriers across the US. Last updated 2023.

  1. Thase ME, et al. 2019 J Clin Psychiatry
  2. Rush AJ, et al. 2006 Am J Psychiatry